By Mrinalika Roy and Medha Singh (Reuters) – Retail investors have flocked to small biotech firms that make women contraceptives after the U.S. Supreme Court last week overturned the Roe v. Wade ruling that recognized the constitutional right to abortion, Vanda Research said on Friday. The landmark decision has turned the spotlight on contraception access and led to a temporary spike in demand for over-the-counter emergency contraceptive pills. Evofem Biosciences and Agile Therapeutics Inc have been biggest beneficiaries, Vanda Research data shows, drawing on average $775,000 and $660,400 in r…